Last reviewed 2026-04-19 · How we verify

TQB3201 tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 1 active Small molecule

TQB3201 tablets is a Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 1 development.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TQB3201 tablets
Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TQB3201 tablets CI brief — competitive landscape report
TQB3201 tablets updates RSS · CI watch RSS
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI

Frequently asked questions about TQB3201 tablets

What is TQB3201 tablets?

TQB3201 tablets is a Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Who makes TQB3201 tablets?

TQB3201 tablets is developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (see full Chia Tai Tianqing Pharmaceutical Group Co., Ltd. pipeline at /company/chia-tai-tianqing-pharmaceutical-group-co-ltd).

What development phase is TQB3201 tablets in?

TQB3201 tablets is in Phase 1.

Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing